Comparing Two Methods of Delivering Mitomycin C for Liver Cancer Treatment in Rats
Author Information
Author(s): A. Marinelli, C.J.H. van de Velde, P.J.K. Kuppen, H.C.M. Franken, J.H.M. Souverijn, A.M.M. Eggermont
Primary Institution: University Hospital, Leiden; Rotterdam Cancer Centre, The Netherlands
Hypothesis
Isolated liver perfusion (ILP) allows for higher doses of mitomycin C to be administered safely compared to hepatic artery infusion (HAI).
Conclusion
Isolated liver perfusion can safely deliver a higher dose of mitomycin C, resulting in significantly higher concentrations in tumor tissue compared to hepatic artery infusion.
Supporting Evidence
- ILP allowed for a four times higher dose of mitomycin C compared to HAI.
- Rats treated with ILP showed no systemic toxicity at higher doses.
- Mitomycin C concentrations in tumor tissue were significantly higher in ILP treated rats.
Takeaway
This study shows that giving a special cancer drug directly to the liver can be safer and more effective than giving it through the bloodstream.
Methodology
The study compared the toxicity and drug concentrations of mitomycin C administered via isolated liver perfusion and hepatic artery infusion in WAG rats.
Limitations
The study was conducted in rats, which may not fully represent human responses.
Participant Demographics
Wistar derived, inbred male WAG/Ola rats, weighing 320-400g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website